Enzon Pharmaceuticals, Inc.
48.60%
36,056,636
727510
293904108
Jun 19, 2025
Jun 23, 2025, 08:19 AM
Reporting Persons (3)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| CARL C ICAHN | Individual | 48.60% | 36,056,636 | 0 | 36,056,636 |
| ICAHN ENTERPRISES HOLDINGS L.P. | Partnership | 48.60% | 36,056,636 | 0 | 36,056,636 |
| ICAHN ENTERPRISES G.P. INC. | CO | 48.60% | 36,056,636 | 0 | 36,056,636 |
Disclosure Items (5)
Common Stock, par value $0.01 per share
Enzon Pharmaceuticals, Inc.
20 Commerce Drive, Suite 135, Cranford, NJ, 07016
Items 2(a)-(c) of the Original 13D are hereby amended and restated as follows: The persons filing this statement are Icahn Enterprises Holdings L.P., a Delaware limited partnership ("Icahn Enterprises Holdings"), Icahn Enterprises G.P. Inc., a Delaware corporation ("Icahn Enterprises GP"), and Carl C. Icahn, a citizen of the United States of America (collectievely, the "Reporting Persons").
The principal business address of each of Icahn Enterprises Holdings and Icahn Enterprises GP is 16690 Collins Avenue, PH-1, Sunny Isles Beach, FL 33160. The principal business address of Mr. Icahn is c/o Icahn Associates Holding LLC, 16690 Collins Avenue, PH-1, Sunny Isles Beach, FL 33160.
Icahn Enterprises Holdings is primarily engaged in the business of holding direct or indirect interests in various operating businesses. Icahn Enterprises GP is primarily engaged in the business of serving as the general partner of each of Icahn Enterprises L.P. and Icahn Enterprises Holdings. Carl C. Icahn's present principal occupation or employment is serving as (i) Chief Executive Officer of Icahn Capital LP, a wholly owned subsidiary of Icahn Enterprises L.P., through which Mr. Icahn manages various private investment funds, (ii) Chairman of the Board of Icahn Enterprises GP, the general partner of Icahn Enterprises L.P., a Nasdaq listed diversified holding company engaged in a variety of businesses, including investment, energy, automotive, food packaging, real estate, home fashion and pharma, and (iii) Chairman of the Board and a director of Starfire Holding Corporation ("Starfire"), a holding company engaged in the business of investing in and/or holding securities of various entities, and as Chairman of the Board and a director of various of Starfire's subsidiaries.
Item 6 of the Original 13D is hereby amended and supplemented as follows: The disclosure set forth in Item 4 of this Schedule 13D is incorporated herein by reference.
The exhibit list in Item 7 of the Original 13D is hereby amended and supplemented by adding the following exhibit: 1. Merger Agreement, dated June 20, 2025 (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Enzon Pharmaceuticals, Inc. on June 23, 2025) 2. Support Agreement, dated June 20, 2025 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by Enzon Pharmaceuticals, Inc. on June 23, 2025)